Literature DB >> 23174751

Personalized treatment of uveal melanoma.

B Damato1, H Heimann.   

Abstract

Personalized treatment of uveal melanoma involves the tailoring of all aspects of care to the condition, needs, wishes, and fears of the patient, taking account of the individual's circumstances. When selecting between radiotherapy, surgical resection, and phototherapy, or when deciding how best to combine these different therapeutic modalities, it is necessary to understand the patients utilities, with respect to tumour control, visual conservation, and preservation of the eye, so as to prioritize outcomes accordingly. For example, such considerations would influence the width of the safety margins when administering radiotherapy, according to whether the patient considers it more important to conserve vision or to guarantee tumour control. With 'suspicious naevi', the choice between observation, immediate treatment, and biopsy is complicated by the lack of adequate survival data on which to base rational decisions, making it necessary for both patient and doctor to accept uncertainty. Personalized care should involve close relatives, as appropriate. It must also adapt to changes in the patient's needs over time. Such personalized care demands the ability to respond to such needs and the sensitivity to identify these requirements in the first place. Personalized treatment enhances not only the patient's satisfaction but also the 'job satisfaction' of all members of the multidisciplinary team, improving quality of care.

Entities:  

Mesh:

Year:  2012        PMID: 23174751      PMCID: PMC3574243          DOI: 10.1038/eye.2012.242

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  28 in total

1.  Differences in uveal melanomas between men and women from the British Isles.

Authors:  B E Damato; S E Coupland
Journal:  Eye (Lond)       Date:  2011-11-11       Impact factor: 3.775

2.  Proton beam radiotherapy of iris melanoma.

Authors:  Bertil Damato; Andrzej Kacperek; Mona Chopra; Martin A Sheen; Ian R Campbell; R Douglas Errington
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-01       Impact factor: 7.038

3.  Vitreoretinal surgery and endoresection in high posterior choroidal melanomas.

Authors:  J García-Arumí; L Sararols; V Martinez; B Corcostegui
Journal:  Retina       Date:  2001       Impact factor: 4.256

4.  Sudden growth of a choroidal melanoma and multiplex ligation-dependent probe amplification findings suggesting late transformation to monosomy 3 type.

Authors:  Sonia A Callejo; Justyna Dopierala; Sarah E Coupland; Bertil Damato
Journal:  Arch Ophthalmol       Date:  2011-07

5.  Endoresection of choroidal melanoma.

Authors:  B Damato; C Groenewald; J McGalliard; D Wong
Journal:  Br J Ophthalmol       Date:  1998-03       Impact factor: 4.638

Review 6.  Local resection of uveal melanoma.

Authors:  Bertil E Damato
Journal:  Dev Ophthalmol       Date:  2011-10-21

Review 7.  Treatment selection for uveal melanoma.

Authors:  Bertil E Damato
Journal:  Dev Ophthalmol       Date:  2011-10-21

8.  Baerveldt implant for secondary glaucoma due to iris melanoma.

Authors:  Annelie N Tan; Juliette G M M Hoevenaars; Carroll A B Webers; Bertil Damato; Henny J M Beckers
Journal:  Clin Ophthalmol       Date:  2010-05-06

9.  Very long-term prognosis of patients with malignant uveal melanoma.

Authors:  Emma Kujala; Teemu Mäkitie; Tero Kivelä
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-11       Impact factor: 4.799

10.  Reconciling the principle of patient autonomy with the practice of informed consent: decision-making about prognostication in uveal melanoma.

Authors:  Sharon A Cook; Bertil Damato; Ernie Marshall; Peter Salmon
Journal:  Health Expect       Date:  2010-10-28       Impact factor: 3.377

View more
  15 in total

1.  Proton beam radiotherapy of uveal melanoma.

Authors:  Bertil Damato; Andrzej Kacperek; Doug Errington; Heinrich Heimann
Journal:  Saudi J Ophthalmol       Date:  2013-07

Review 2.  The potential complementary role of targeted alpha therapy in the management of metastatic melanoma.

Authors:  Michael P Brown; Eva Bezak; Barry J Allen
Journal:  Melanoma Manag       Date:  2015-11-24

3.  Two-year patient-reported outcomes following treatment of uveal melanoma.

Authors:  L Hope-Stone; S L Brown; H Heimann; B Damato; P Salmon
Journal:  Eye (Lond)       Date:  2016-09-02       Impact factor: 3.775

4.  Comparison between patient-reported outcomes after enucleation and proton beam radiotherapy for uveal melanomas: a 2-year cohort study.

Authors:  Laura Hope-Stone; Stephen L Brown; Heinrich Heimann; Bertil Damato
Journal:  Eye (Lond)       Date:  2019-04-15       Impact factor: 3.775

Review 5.  Predictors of emotional distress in uveal melanoma survivors: a systematic review.

Authors:  Cari Davies; Stephen Lloyd Brown; Peter Fisher; Laura Hope-Stone; Debra Fisher; Andrew Morgan; Mary Gemma Cherry
Journal:  Eye (Lond)       Date:  2022-08-08       Impact factor: 4.456

Review 6.  Molecular pathology of uveal melanoma.

Authors:  S E Coupland; S L Lake; M Zeschnigk; B E Damato
Journal:  Eye (Lond)       Date:  2012-12-07       Impact factor: 3.775

Review 7.  Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging-Part II: treatment indications and complications.

Authors:  Pietro Valerio Foti; Mario Travali; Renato Farina; Stefano Palmucci; Corrado Spatola; Rocco Luca Emanuele Liardo; Roberto Milazzotto; Luigi Raffaele; Vincenzo Salamone; Rosario Caltabiano; Giuseppe Broggi; Lidia Puzzo; Andrea Russo; Michele Reibaldi; Antonio Longo; Paolo Vigneri; Teresio Avitabile; Giovani Carlo Ettorre; Antonio Basile
Journal:  Insights Imaging       Date:  2021-06-04

8.  Minimal contribution of ERK1/2-MAPK signalling towards the maintenance of oncogenic GNAQQ209P-driven uveal melanomas in zebrafish.

Authors:  Mai Abdel Mouti; Christopher Dee; Sarah E Coupland; Adam F L Hurlstone
Journal:  Oncotarget       Date:  2016-06-28

Review 9.  Mechanisms of phosphenes in irradiated patients.

Authors:  Thibaud Mathis; Stephane Vignot; Cecila Leal; Jean-Pierre Caujolle; Celia Maschi; Martine Mauget-Faÿsse; Laurent Kodjikian; Stéphanie Baillif; Joel Herault; Juliette Thariat
Journal:  Oncotarget       Date:  2017-06-28

Review 10.  Personalized medicine in Europe: not yet personal enough?

Authors:  Antonello Di Paolo; François Sarkozy; Bettina Ryll; Uwe Siebert
Journal:  BMC Health Serv Res       Date:  2017-04-19       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.